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It is now clear that angiogenesis and angiogenesis factors are important in the pathogenesis of haematological malignancies.
High pretreatment levels of serum basic ﬁbroblast growth factor have been shown to be associated with poor prognosis in
patients with non-Hodgkin’s lymphoma. The aim of this study was to evaluate whether non-Hodgkin’s lymphoma cells express
basic ﬁbroblast growth factor and/or its receptor (ﬁbroblast growth factor receptor-1) and whether basic ﬁbroblast growth
factor expression correlates with basic ﬁbroblast growth factor serum levels, intratumoral microvessel density, and patient
outcome. We measured basic ﬁbroblast growth factor by enzyme-linked immunosorbent assay in sera taken from 58 patients
with non-Hodgkin’s lymphoma before treatment and in 19 of them also after treatment. Pathological specimens at diagnosis
were evaluated by immunohistochemistry staining using polyoclonal antibody against factor-VIII-related antigen, basic ﬁbroblast
growth factor and ﬁbroblast growth factor receptor-1 to determine the expression of the microvessel count and basic
ﬁbroblast growth factor and ﬁbroblast growth factor receptor-1. The lymphoma specimens demonstrated positive staining for
basic ﬁbroblast growth factor (in 23%) and ﬁbroblast growth factor receptor-1 (in 58.5%). The patients who expressed basic
ﬁbroblast growth factor had a signiﬁcantly worse progression-free and overall survival than those who did not (P=0.003 and
P=0.03 respectively), while patients expressing ﬁbroblast growth factor receptor-1 were less likely to achieve complete
remission than those lacking the receptor (33% vs 65% , P=0.047). There was no correlation of basic ﬁbroblast growth factor
staining with either serum basic ﬁbroblast growth factor levels or microvessel count. Basic ﬁbroblast growth factor serum levels
did not change signiﬁcantly after treatment These results suggest that non-Hodgkin’s lymphoma specimens express basic
ﬁbroblast growth factor and its receptor (ﬁbroblast growth factor receptor-1) and this expression is associated with poor
patient outcome.
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Angiogenesis is necessary for the growth of solid tumours and
the dissemination of malignant cells (Folkman, 1990). Recent
evidence also points to a role of angiogenesis and angiogenesis-
related molecules in haematological malignancies (Mangi and
Newland, 2000). Tumours promote angiogenesis by secreting
growth factors that stimulate endothelial cell migration and capil-
lary proliferation. Angiogenic activity is regulated by the balance
between positive and negative angiogenic regulators (Iruela-Arispe
and Dvorak, 1997). Basic ﬁbroblast growth factor (bFGF), an 18-
to 24-kD polypeptide, serves as a key positive angiogenic regula-
tor in vivo (Bikfalvi et al, 1997). It also stimulates endothelial
cell proliferation in vitro and regulates the expression of several
molecules thought to mediate critical steps in the angiogenesis
process (Basilico and Moscatelli, 1992). bFGF is mainly produced
by cells of mesenchymal origin. T cells, macrophages, and gran-
ulocytes also have the capacity to produce bFGF (Salven et al,
1999). It is normally bound to heparin and heparan sulphate
proteoglycans in the extracellular matrix, particularly in basement
membranes, around vessels and stromal cells. It binds to a family
of four distinct, high-afﬁnity tyrosine kinase receptors, designated
FGFR-1–4.
Until recently, measurement of intratumoral microvessel density
by immunocytochemistry appeared to be the most reliable method
of assessing angiogenic activity (Toi et al, 1996). An alternative
method for evaluating angiogenic activity is the determination of
the levels of each angiogenic factor in tumour tissues and serum
(Poon et al, 2001). There are very few studies of angiogenesis in
non-Hodgkin’s lymphoma (NHL). Ribatti and his group (Ribatti
et al, 1996) assessed the microvessel count with factor VIII staining
in 88 patients with NHL and 15 with benign lymphadenopathies.
Their count covered the whole specimens. They found that angio-
genesis is more intense in the stroma of B-NHL than of benign
lymphadenopathies, and increases in more aggressive tumours. In
lymphadenopathies and follicular subtypes of NHL, very few vessels
were observed within follicles, and numerous in uninvolved tissue
between the follicles. By contrast, all diffuse subtypes of NHL
showed vessels throughout the tumour tissue. Salven et al (1999)
measured serum bFGF in 160 newly diagnosed patients with
NHL and found that a high pretreatment serum bFGF was asso-
ciated with poor overall survival.
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www.bjcancer.comIn the present study, we measured serum bFGF concentration
before and after treatment in patients with NHL. We also
conducted a biopsy study to determine the expression of bFGF
and its receptor FGFR-1 and the microvessel count (MVC) in
biopsies taken at diagnosis. Finally, we evaluated the prognostic
signiﬁcance of bFGF and FGFR-1 expression in NHL patients.
PATIENTS AND METHODS
Patients
Serum bFGF concentration was measured in 58 adult patients with
NHL diagnosed and treated in the Division of Hematology, Rabin
Medical Center, Beilinson Campus from 1997 to 1999. Approval
was obtained from the local ethics committee. Serum was taken
at the time of diagnosis, before lymphoma treatment was adminis-
tered. In 19 patients, serum bFGF concentration was also measured
after 2–3 cycles of chemotherapy.
The clinical and pathological characteristics of the patients are
shown in Table 1.There were 26 male (45%) and 32 females
(55%) of mean age 64.5 years (range 25–90).The histological types
according to the WHO classiﬁcation (Harris et al, 1999) were as
follows: small lymphocytic lymphoma, six patients (10%); follicular
lymphoma, 11 patients (19%); diffuse large B-cell lymphoma
(DLBCL), 36 patients (62%); extranodal marginal zone B-cell
lymphoma, one patient (2%); mantle cell lymphoma, three patients
(5%), and precursor T-lymphoblastic lymphoma, 1 patient (2%).
Clinical staging at diagnosis was done according to the Ann Arbor
classiﬁcation system: 13 (22%) patients had stage I, ﬁve (9%) stage
II, eight (14%) stage III, and 32 (55%) stage IV. Sixteen specimens
(27%) were of extranodal origin and the rest were of nodal origin.
Seventeen patients (29%) had bulky disease at presentation (largest
diameter 510 cm) and 20 (34.5%) had elevated serum lactate
dehydrogenase (LDH) levels at diagnosis. The International Prog-
nostic Index (IPI) (The International Non-Hodgkin’s Prognostic
Factor Project, 1993) was determined in 56 patients. The score
was 0 in seven patients (12.5%); one in eight patients (14%);
two in 16 patients (28.5%); three in 14 patients (25%); four in
six patients (11%), and ﬁve in ﬁve patients (9%).
Eleven patients did not receive any treatment. Four patients
received only radiotherapy and another four received radiation
combined with chemotherapy. Low-grade lymphomas were usually
treated with chlorambucil alone or combined with prednisone if
symptomatic. Intermediate-grade lymphomas were usually treated
with CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisone) or another anthracycline-containing combination
chemotherapy regimen. Three patients underwent stem cell trans-
plantation, two autologous and one allogeneic.
Median follow-up time was 29.5 months (range 1–49). During
follow-up, 13 patients died.
Methods
Serum bFGF immunoassay Peripheral venous blood samples
were collected in empty tubes, centrifuged at 2000 g for 10 min,
and stored at 7708C. The level of bFGF in serum was determined
with a commercial quantitative sandwich enzyme immunoassay
technique (Quantikine R; R&D Systems, Minneapolis, MN, USA).
The system uses a solid-phase monoclonal antibody and an
enzyme-linked polyclonal antibody raised against recombinant
human bFGF. All analyses and calibrations were performed in
duplicate.
Immunohistochemistry for factor-VIII-related antigen, bFGF
and FGFR-1 All specimens were archival material of biopsies
taken at the time of lymphoma diagnosis that had been ﬁxed in
neutral-buffered formalin and embedded in parafﬁn by routine
methods. Parafﬁn-embedded tumour specimens were cut into 4-
mm thick sections and mounted on adhesive-coated glass slides.
Deparafﬁnisation and hydration were performed through xylene
and graded alcohol series. The slides were washed in distilled water
and heated twice in citrate buffer (pH 6.0) in a pressure cooker
that was placed in a microwave oven for 15 and 5 min at 700 W
to retrieve the antigenicity. Endogenous peroxidase activity was
then blocked by incubation for 15 min at room temperature with
H2O2 (3%) in methanol followed by washing with phosphate-
buffered saline (PBS). The slides were then incubated with one
of the following primary antibodies: (1) rabbit anti-human, anti-
factor-VIII-related antigen (F8RA), (Dako, CA, USA) at a dilution
of 1:1000 for 45 min at room temperature; (2) rabbit anti-human,
anti-bFGF polyclonal antibody (Biotechnology, Inc; Santa Cruz,
CA, USA) at a dilution of 1:500 for 45 min at room temperature;
(3) rabbit anti-human, anti-FGFR-1 polyclonal antibody (Biotech-
nology, Inc.) at a dilution of 1:800 for 45 min at room
temperature. The primary antibodies against F8RA and FGFR-1
were detected by the Strept A-B immunoperoxidase staining
universal kit (LSAB
+ Kit, Dako) according to the manufacturer’s
instructions. The primary antibody against bFGF was detected by
the DAKO EnVision
TM+ System. This system is based on HRP-
labelled polymer that does not contain avidin or biotin and there-
fore eliminates nonspeciﬁc staining from endogenous avidin-biotin
activity, which was very high with the Dako LSAB
+ kit. Diamino-
benzidine was used as chromogen, and incubation was conducted
for 5 min at room temperature. Sections were counterstained in
haematoxylin. A negative control omitting the primary antibody
was used in each experiment. For positive control of bFGF, we
stained specimens of normal breast, in which bFGF is known to
be localised in the myoepithelial cells (Yiangou et al, 1997). For
positive control of FGFR-1, we stained specimens of breast carcino-
ma which is known to display FGFR-1 expression in neoplastic
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 1 Characteristics of 58 NHL patients
Mean age (years) 64.5
Range (years) 25–90
Sex
Female 32 (55%)
Male 26 (45%)
Pathology-hostological type Small lymphocytic lymphoma 6 (10%)
Follicular lymphoma 11 (19%)
Diffuse large B-cell lymphoma 36 (62%)
Extranodal marginal zone B-cell lymphoma 1 (2%)
Mantle cell lymphoma 3 (5%)
Precursor T-lymphoblastic lymphoma 1 (2%)
Stage
I 13 (22%)
II 5 (9%)
III 8 (14%)
IV 32 (55%)
Extranodal 16 (27%)
Bulky disease (410 cm) 17 (29%)
Elevated serum LDH 20 (34.5%)
International Prognostic Index:
0 7 (12.5%)
1 8 (14%)
2 16 (28.5%)
3 14 (25%)
4 6 (11%)
5 5 (11%)
Median follow-up time (months) 29.5
Range 1–49
Treatment
None 11 (19%)
Radiotherapy 4 (7%)
Radiotherapy and chemotherapy 4 (7%)
Chemotherapy 43 (74%)
Stem cell transplantation 3 (5%)
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node showed positive staining for bFGF and negative staining for
FGFR-1, which did stain the blood vessels.
Immunohistological scoring The areas of highest protein expres-
sion evident at low-power scanning were taken for analysis.
Staining was considered negative only after careful examination
of the entire tissue section under high power (61000). Quantita-
tion of the number of positive tumour cells was performed
simultaneously by two investigators (I Pazgal, O Bairey) blinded
to the clinical outcome. A double-headed light microscope was
used to score at least 500 cells in high power ﬁelds. In cases in
which the investigators disagreed, the immunohistochemical stain-
ing was repeated, and a third reviewer (E Okon) scored the slides
in a blinded fashion. Specimens that contained 410% immunos-
tained tumour cells were deﬁned as immunopositive; those with
410% were deﬁned as immunonegative.
Microvessel count Microvessel count (MVC) was assessed with a
light microscope. The whole tumour section was scanned at a low
magniﬁcation (6100), and the area of the most intense vasculari-
sation (hot spot) was determined. Any brown-staining endothelial
cell or endothelial-cell cluster that was clearly separated from adja-
cent microvessels, tumour cells and connective tissue elements was
considered a single countable microvessel. The presence of a vessel
lumen was not necessary for a structure to be deﬁned as a micro-
vessel. Vessels within sclerotic areas were not included. Individual
microvessel counts were made on a 6200 field (0.785 mm
2 per
ﬁeld). Quantitation of the number of microvessels was performed
simultaneously and independently by two investigators (O Bairey,
I Pazgal) blinded to the clinical outcome. The mean number of
microvessels per sample was calculated and was taken as the
MVC for each case.
Statistical analysis Statistical analysis was performed using an
SPSS statistical software program (SPSS Inc. Chicago, IL, USA).
Either t-test or w
2 analysis (Fisher exact test) was used for statistical
comparison of the clinical and laboratory characteristics and bFGF
serum levels or bFGF and its receptor expression and MVC. Analy-
sis of Variance (ANOVA) was used to compare bFGF levels
between different clinical groups. Progression-free survival (PFS)
was calculated from date of diagnosis to date of disease progres-
sion, relapse or death. Survival and PFS were computed
according to the product-limit method of Kaplan-Meier from the
date of diagnosis. The log rank test was used to compare survival
rates between different subgroups of patients. The relative inﬂuence
of different variables on survival was studied by multivariate survi-
val analysis using stepwise Cox regression.
RESULTS
Serum bFGF in patients at diagnosis and after treatment
Mean serum bFGF concentration in 11 healthy volunteers was
2.5+3.8 pg ml
71 (range 0–10.5). Serum bFGF concentrations in
58 patients with NHL ranged from undetectable to 28.0 pg ml
71
(mean 5.3+5.6 pg ml
71). There were no signiﬁcant differences
in serum bFGF concentration by NHL grade, histologic type, stage
of disease, IPI index, or treatment protocol. There was also no
association between serum bFGF level and patient age, sex and
LDH levels. Patients with bulky NHL had signiﬁcantly higher levels
of bFGF (410 pg ml
71) than patients with non-bulky disease
(29.4% and 7.7% respectively, P=0.046); no correlation with either
overall survival or PFS was found.
In 19 patients, serum bFGF was also assayed after 2–3 cycles of
chemotherapy. Mean bFGF level at that time was 9.6 pg ml
71
(range 0–21.8). There was no correlation between serum bFGF
level at diagnosis and after treatment, nor was there a signiﬁcant
change in bFGF levels or a speciﬁc trend in patients responding
or not responding to treatment.
Microvessel count (MVC)
Mean MVC, determined in 40 patients was 77.3+35.7 (range 20–
197). Follicular lymphoma specimens demonstrated a distinct
pattern of microvessel distribution, with very few microvessels in
the area of the follicles but numerous ones in the areas between
the follicles (Figure 1). Since the vessels were counted in the areas
of most intense vascularisation, (hot spots), in the follicular
lymphomas specimens, these areas were always in the interfollicular
areas. No correlation was found between mean MVC and grade,
stage histology or survival of the patients.
bFGF expression in lymphoma specimens (Figure 3A)
Staining of lymphoma specimens for bFGF was performed in 39
patients. In nine patients the lymphomas expressed bFGF
(23.1%). There was heterogeneity of bFGF expression with a mean
staining of 51% of lymphoma cells (range 15–100%). In most
specimens endothelial cells, polymorphonuclear cells, and macro-
phages stained positive and served as an internal positive control.
Positive immunostaining for bFGF was usually present in the cyto-
plasm of tumour cells, but some cells showed nuclear staining.
Lymphoma cell staining correlated strongly with PFS (P=0.003,
Table 2, Figure 2A) and overall survival (P=0.03, Table 2, Figure
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Figure 1 Microvessels in NHL. Representative ﬁeld of follicular NHL (A)
and diffuse NHL (B) stained with anti-factor-VIII-related antigen. Note the
absence of microvessels in the follicular area.
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worse PFS and overall survival. In the nine patients in whom the
lymphoma cells stained positive, mean survival was 23.8+5.8
months (range 1–38; median survival was not reached)) and mean
PFS was 17.9+5.1 months (range 1–38, median 13 months). Four
of them died during the study period, and only 33% had no
disease progression. By contrast, of the 30 patients whose speci-
mens stained negative for bFGF, mean survival was 43.5+2.6
months (range 1–49, median survival was not reached) and mean
PFS 41.2+2.9 months (range 1–49, median PFS was not reached).
Only four patients from this group died during the study period,
and 80% had no disease progression. When survival analysis were
carried out in the 25 patients with diffuse large B-cell lymphoma
(DLBCL), the patients in whom the lymphoma specimens stained
positive for bFGF had signiﬁcantly worse overall (P=0.013) and
PFS (P=0.002, Table 2). There was also a correlation between bFGF
staining and bulky disease. Five of the nine patients with lympho-
ma which was positive for bFGF staining (55.6%) had bulky
disease compared to 17.9% of the patients with lymphoma with
negative staining (P=0.04). No correlation was found between
bFGF staining and serum bFGF concentration, MVC, histology,
stage, grade, LDH level, IPI index, or response to treatment.
bFGF receptor expression in lymphoma specimens (Figure
3B)
Staining of lymphoma specimens for bFGF receptor (FGFR-1) was
performed in 41 patients. Results were positive in 24 (58.5%). In
most of the positive specimens the staining was cytoplasmatic,
but in some, additional nuclear staining or only nuclear staining
was evident. Endothelial cells stained positive as did plasma cells,
and they served as an internal positive control. A correlation was
found between a negative expression of FGFR-1 and the achieve-
ment of complete remission (P=0.047). Eleven of the 17 patients
with lymphomas with negative staining for FGFR-1 (64.7%)
achieved complete remission compared to only eight of the 24
patients with lymphomas with positive staining (33.3%). There
was also a borderline correlation between FGFR-1 expression and
bulky disease (P=0.07), with 39% of the patients with lymphomas
that expressed FGFR-1 having bulky disease compared to 12.5% of
patients with lymphomas who did not. A borderline correlation
was noted between the expression of bFGF and its receptor
(P=0.067): 87.5% of the patients who expressed bFGF in their
lymphomas, also expressed FGFR-1, compared to only 50% of
the patients who’s lymphomas did not express bFGF. No correla-
tion was found between FGFR-1 staining and serum bFGF
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Figure 3 Staining of small lymphocytic lymphoma cells for bFGF (A),
FGFR-1 (B).
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Figure 2 Kaplan–Meier progression-free survival (A) and overall survi-
val (B) curves according to bFGF expression for 39 patients with NHL.
bFGF expression was positive in lymphomas from nine patients (23%).
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or overall survival. When survival analysis was carried out for
the 24 patients with DLBCL group alone, there was a signiﬁcant
worse PFS for the patients with positive staining (P=0.035, Table
2) and borderline worse overall survival (P=0.075, Table 2).
Prognostic studies
The prognosis of patients with NHL is best determined by the IPI
index and this was conﬁrmed by the present study (P=0.002).
Multivariate analysis by Stepwise Cox regression was used to deter-
mine if bFGF expression adds to the predictive value of the IPI for
survival. IPI alone still had the strongest predictive value.
DISCUSSION
The results presented show that bFGF and its receptor FGFR-1 are
expressed in NHL. Furthermore, the expression of bFGF and its
receptor in lymphoma cells has a prognostic signiﬁcance: bFGF
expression is correlated with worse survival and PFS, and FGFR-
1 expression is correlated with decreased rate of achievement of
complete remission and in the subgroup with DLBCL with worse
survival and PFS. Thus, bFGF and its receptor might be involved
in the survival and resistance to therapy of NHL cells.
Several lines of evidence have suggested a role of ﬁbroblast
growth factors (FGFs) and their receptors (FGFRs) in human
cancer (Birnbaum et al, 1991). Basilico and Moscatelli (1992)
found that ampliﬁcation or ectopic expression of FGFs induces
cellular transformation. Several carcinomas have shown increased
bFGF production by the cancer epithelial cell themselves observed
by immunohistochemistry. These include pancreatic (Ohta et al,
1995; Yamazaki et al, 1997) breast (Yiangou et al, 1997; Blanckaert
et al, 1998), non-small cell lung (Volm et al, 1997) and head and
neck squamous carcinomas (Dellacono et al, 1997). FGFR-1 and
FGFR-2 are overexpressed in several human cancers (Birnbaum
et al, 1991; Ohta et al, 1995; Yamazaki et al, 1997; Blanckaert et
al, 1998), and some investigators noted a prognostic signiﬁcance
of bFGF expression or bFGF receptors only. In pancreatic carcino-
mas, expression of bFGF was strongly associated with the tumour
cell proliferation (Yamazaki et al, 1997) and with poor prognosis.
Ohta et al (1995) reported that increased FGFR-1 expression in
pancreatic carcinomas was correlated with decreased survival. In
non-small cell lung carcinomas, all tumour specimens expressed
some level of bFGF and FGFR-1 (Volm et al, 1997). Patients with
high FGFR-1 expression had signiﬁcantly shorter survival than
patients with weak or moderate expression, but no correlation
was found between bFGF expression and patient survival. In
patients with breast carcinomas, higher levels of bFGF levels were
associated with improved overall and disease-free survival (Yiangou
et al, 1997); However, bFGF was expressed less in the malignant
tissue than the non-malignant breast tissue. In the study of Blanck-
aert et al (1998) almost all breast tumours contained high-afﬁnity
bFGFR, and the patients expressing high levels of bFGFR had a
more favourable prognosis. In prostate cancer, Giri et al (1999)
found that bFGF is signiﬁcantly increased relative to the normal
prostate tissue and that it is localised in stromal ﬁbroblasts and
endothelial cells but not malignant cells. In a subset of prostate
cancers, however, these authors observed overexpression of both
FGFR-1 and FGFR-2 in the epithelial cells, which correlated with
poor differentiation.
Recently, intracellular bFGF has been detected in several
lymphoproliferative diseases and was associated with more
advanced or refractory disease. In B cells derived from chronic
lymphocytic leukaemia, elevated levels of intracellular levels were
correlated with disease stage and were associated with resistance
to ﬂudarabine (Menzel et al, 1996). Gruber et al (1999) showed
that in hairy cell leukaemia, another type of chronic B-cell leukae-
mia, the leukemic cells express bFGF, which in turn, may mediate
the resistance to chemotherapy and survival of the malignant cells.
Vacca et al (1999) were the ﬁrst to demonstrate a signiﬁcant
increase in bone marrow angiogenesis (evaluated as microvessel
area) in patients with active multiple myeloma (MM) compared
with patients with nonactive MM and monoclonal gammopathy
of undetermined signiﬁcance (MGUS). Evaluation of bFGF in
plasma cell lysates by immunoassay showed signiﬁcantly higher
levels in cells of the patients with active MM compared with
nonactive MM and MGUS patients. However, when all the
patients were considered, there was no signiﬁcant correlation
between individual plasma cell bFGF levels and bone marrow
neovascularisation. It has recently been reported that patients with
MM who respond to chemotherapy show a signiﬁcant decrease in
serum bFGF levels, whereas nonresponders do not (Sezer et al,
2001).
In the present study, we did not detect a signiﬁcant change in
serum bFGF levels after 2–3 cycles of chemotherapy, nor did we
ﬁnd a correlation between MVC and NHL histology or grade or
between MVC and prognosis. One explanation might be the micro-
vessel counting method used. We did observe a lack of microvessels
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Table 2 Survival analysis for I. All WHO groups. II. DLBCL group
Expression
Mean PFS
(months)
Median PFS
(months) P value
Mean overall survival
(months)
Median overall survival
(months) P value
i. All WHO groups
bFGF positive 17.9 13 23.8 Not reached
bFGF negative 41.2 Not reached 0.003 43.5 Not reached 0.03
FGFR-1 positive 33.7 Not reached Not
FGFR-1 negative 39 Not reached signiﬁcant
Normal LDH level 40.1 Not reached 46.0 Not reached
Increased LDH level 24.4 22.0 0.012 28.9 Not reached 0.0025
IPI index 0–2 40.0 Not reached 47.0 Not reached
IPI index 3–5 26.2 Not reached 0.045 28.8 Not reached 0.0019
Serum bFGF 43.5 35.9 Not reached Not 39.6 Not reached Not
Serum bFGF 43.5 33.8 Not reached signiﬁcant 38.7 Not reached signiﬁcant
II. DLBCL group
bFGF positive 15.4 13 19.4 13
bFGF negative 39.3 Not reached 0.002 39.5 Not reached 0.013
FGFR-1 positive 25.5 21 27.7 Not reached
FGFR-1 negative 40.4 Not reached 0.035 40.42 Not reached 0.075
Stages I and II 35.2 Not reached 35.96 Not reached Not
Stages III and IV 23.9 14 0.02 30.05 Not reached signiﬁcant
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were many microvessels in the interfollicular areas, and those areas
with the greatest number of microvessels (‘hot spots’) were
counted.
Unlike Salven et al (1999), we did not ﬁnd that pretreatment
serum bFGF level is associated with poor overall survival. This
difference might be attributable to the relatively small number of
patients in our study. Nevertheless, the sample was large enough
to yield a highly signiﬁcant correlation between bFGF expression
and poor PFS and overall survival. We also found that the MVC
did not correlate with the expression of bFGF, the expression of
its receptor, or patient survival. This might suggest that the auto-
crine or paracrine loop involving the lymphoma cells is more
important in NHL than the paracrine loop involving the endothe-
lial cells.
Beside autocrine loop activation, lymphoma cells expressing
bFGFRs may respond to bFGFs produced by other cell types or
released from the extracellular matrix in a paracrine fashion. We
speculate that as the tumour becomes more aggressive, it also
becomes independent of stromal paracrine factors by the establish-
ment of an autocrine FGF stimulation that can increase its
tumorigenicity.
Our results suggest that bFGF within the lymphoma cells plays
an important role in the pathogenesis of NHL and can identify
patients with poor outcome. The present study is small and hetero-
geneous. Further larger studies are required examining speciﬁc
types of lymphoma to determine in what subtypes the effect is
most signiﬁcant. If true, agents that can suppress bFGF synthesis
might have a role in the treatment of resistant NHL. Strategies
aimed at decreasing the expression of bFGF and its receptor may
be of therapeutic beneﬁt in poor-prognosis NHL.
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